Go Pro
→ Elon Warns 'America Will Go Bankrupt'. Trump's Plan Inside. (From American Hartford Gold) (Ad)tc pixel
NASDAQ:SNY

Sanofi Q3 2026 Earnings Report

Sanofi logo
$39.92 -0.75 (-1.84%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$40.02 +0.10 (+0.25%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Sanofi EPS Results

Actual EPS
N/A
Consensus EPS
$1.72
Beat/Miss
N/A
One Year Ago EPS
N/A

Sanofi Revenue Results

Actual Revenue
N/A
Expected Revenue
$15.20 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sanofi Announcement Details

Quarter
Q3 2026
Date
10/30/2026
Time
Before Market Opens
Conference Call Date
Friday, October 30, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Sanofi Earnings Headlines

Sanofi (NASDAQ:SNY) Stock Rating Cut to Hold at Wall Street Zen
October 3 at 1:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081529
Regeneron, Sanofi expand immunology alliance with $1B upfront payment: Here are the key highlights
October 1 at 10:57 AM  |  msn.comhttps://www.msn.com/en-in/news/other/regeneron-sanofi-expand-immunology-alliance-with-1b-upfront-payment-here-are-the-key-highlights/ar-AA2dlATz
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
 |  Stansberry Research (Ad)
Sanofi, Regeneron Expand Immunology Partnership in $1 Billion Deal
October 1 at 5:56 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sanofi-regeneron-expand-immunology-partnership-075335028.html
Sanofi & Regeneron Expand Alliance With Four Next-Gen Antibodies
October 1 at 5:56 AM  |  rttnews.comhttps://www.rttnews.com/3695590/sanofi-regeneron-expand-alliance-with-four-next-gen-antibodies.aspx
Sanofi, Regeneron Expand Immunology Alliance In Deal Worth Up To $8 Bln
October 1 at 5:56 AM  |  rttnews.comhttps://www.rttnews.com/3695635/sanofi-regeneron-expand-immunology-alliance-in-deal-worth-up-to-8-bln.aspx
See More Sanofi Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sanofi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sanofi and other key companies, straight to your email.

About Sanofi

Sanofi (NASDAQ:SNY) is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business. Sanofi serves patients, healthcare providers and public health organizations in markets across North America, Europe, Asia and other regions worldwide.

Sanofi traces its modern corporate history to the formation and combination of several French pharmaceutical businesses, including Sanofi-Synthélabo and Aventis. The company adopted the Sanofi name in 2011 and is headquartered in Paris. Paul Hudson has served as Sanofi’s chief executive officer since 2019.

View Sanofi Profile
Earnings Tools